Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma's Rik Deitsch Interviewed by The Life Sciences Report
October 22, 2015

SAN FRANCISCO, CA--(Marketwired - October 22, 2015) - Nutra Pharma Corp. (OTC PINK: NPHC) is pursuing a strategy of over-the-counter sales as it advances a therapeutic pipeline based on cobra toxin. In this interview with The Life Sciences Report, CEO Rik Deitsch elaborates on the plan to grow the company through distribution of Nutra Pharma's pain medications in India, China, Canada and the U.S., and how therapies based on the toxin can address a variety of autoimmune diseases.

The Life Sciences Report: How is Nutra Pharma Corp. being transformed from a company known for making over-the-counter (OTC) pain medications into one that develops therapeutics for pain, HIV and autoimmune diseases?

Rik Deitsch: In early 2003, we were working on a multiple sclerosis drug, an HIV drug and on autoimmune diseases across the board. We started speaking with the FDA in 2009 about an ethical pain therapy that uses microgram doses of cobra venom extract as a neurotoxin, or neuro blocker, for pain and inflammation. We planned to develop oral, topical and injectable versions of this therapy.

The FDA told us our drug qualified as an OTC homeopathic medication because it is derived from a natural product and because the dosage is so small. That allowed us to create our first OTC drugs in 2009-2010.

Now we have seven SKUs (stock keeping units) of Nyloxin, which is our OTC pain treatment for humans, and one SKU of Pet Pain-Away for dogs and cats. We're trying to build the OTC marketplace to fund…

Continue reading this interview: OTC Strategy Supports Cobra Venom Pipeline in Asia and North America: Nutra Pharma's Rik Deitsch

http://ctt.marketwire.com/?release=11G068575-001&id=7430575&type=0&url=http%3a%2f%2fwww.thelifesciencesreport.com%2fpub%2fna%2fotc-strategy-supports-cobra-venom-pipeline-in-asia-and-north-america-nutra-pharmas-rik-deitsch

About Streetwise Reports -- The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

SEC Disclaimer

DISCLOSURE:

Nutra Pharma Corp. is a sponsor of Streetwise Reports. Mr. Deitsch had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Deitsch and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet


June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto


May 31, 2017
Nutra Pharma Announces Collaboration with the University of Maryland Bioprocess Scale-Up Facility in Preparation of Material for Phase II Studies


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics